- Pharma
- 1 min read
Forward Pharma loses appeal in Tecfidera patent dispute with Biogen
The U.S. Court of Appeals for the Federal Circuit said it agreed with a March 2017 ruling by the Patent Trial and Appeal Board that freed Bigoen Inc from future royalty payments to Forward.
A U.S. appeals court on Wednesday upheld a ruling that patents owned by Biogen Inc covering its blockbuster multiple sclerosis drug Tecfidera are valid, rejecting a challenge by Danish drugmaker Forward Pharma A/S.
The U.S. Court of Appeals for the Federal Circuit said it agreed with a March 2017 ruling by the Patent Trial and Appeal Board that freed Bigoen Inc from future royalty payments to Forward.
Join the community of 2M+ industry professionals
Subscribe to our newsletter to get latest insights & analysis.
COMMENTS
All Comments
By commenting, you agree to the Prohibited Content Policy
PostBy commenting, you agree to the Prohibited Content Policy
PostFind this Comment Offensive?
Choose your reason below and click on the submit button. This will alert our moderators to take actions